First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640
AACR Annual Meeting
Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for the treatment of NASH
EASL International Liver Congress
PRESS RELEASES
3-V Biosciences to Present Data at the American Association for the Study of Liver Diseases Annual Meeting 2016 in Boston, MA
Menlo Park, California, November 04, 2016. 3-V Biosciences, Inc., a clinical-stage pharmaceutical company developing therapeutics for liver diseases, including non-alcoholic
Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640
International Congress on Targeted Anticancer Therapies
